CL2019002629A1 - Análogos de deutetrabenazina, su preparación y uso. - Google Patents
Análogos de deutetrabenazina, su preparación y uso.Info
- Publication number
- CL2019002629A1 CL2019002629A1 CL2019002629A CL2019002629A CL2019002629A1 CL 2019002629 A1 CL2019002629 A1 CL 2019002629A1 CL 2019002629 A CL2019002629 A CL 2019002629A CL 2019002629 A CL2019002629 A CL 2019002629A CL 2019002629 A1 CL2019002629 A1 CL 2019002629A1
- Authority
- CL
- Chile
- Prior art keywords
- deutetrabenazine
- analogs
- preparation
- compositions
- same
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical class C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 229950005031 deutetrabenazine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Pens And Brushes (AREA)
- Machine Translation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002629A1 true CL2019002629A1 (es) | 2020-01-24 |
Family
ID=61873991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002629A CL2019002629A1 (es) | 2017-03-15 | 2019-09-13 | Análogos de deutetrabenazina, su preparación y uso. |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI772382B (zh) | 2017-03-15 | 2022-08-01 | 美商奧斯拜客斯製藥有限公司 | 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途 |
| JP2022519007A (ja) | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| US12599598B2 (en) | 2020-06-10 | 2026-04-14 | Auspex Pharmaceuticals Llc | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| CN115916154A (zh) * | 2020-06-10 | 2023-04-04 | 奥斯佩克斯医药公司 | 包括氘代丁苯那嗪的渗透剂型及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20120003330A1 (en) | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| AU2014357518A1 (en) | 2013-12-03 | 2016-06-09 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| PL3265085T3 (pl) | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| TWI772382B (zh) | 2017-03-15 | 2022-08-01 | 美商奧斯拜客斯製藥有限公司 | 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途 |
-
2018
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en not_active Ceased
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 BR BR112019018966-1A patent/BR112019018966A2/pt not_active Application Discontinuation
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es not_active Application Discontinuation
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US12502385B2/en active Active
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
-
2025
- 2025-11-25 US US19/399,905 patent/US20260144785A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001910A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| CL2020001271A1 (es) | Inhibidores de kras g12c | |
| DOP2018000175A (es) | Inhibidores de la proteína quinasa 1 que interactua con el receptor | |
| CR20180320A (es) | Compuestos inhibidores de la quinasa de union a tank | |
| MX2021006977A (es) | Anellosomas y metodos de uso. | |
| CO2019011271A2 (es) | Análogos de deutetrabenazina, su preparación y uso | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
| DOP2016000145A (es) | Reguladores de nrf2 | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| UY37410A (es) | Antagonistas de trpv4 | |
| UY37015A (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| MX2016011176A (es) | Polipeptidos fhbp meningococicos modificados. | |
| CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| MX2018007084A (es) | Inhibidores de la tirosina quinasa de bruton y metodos de su uso. | |
| PY18111999A (es) | Hidroxiisoxazolinas y derivados de estos | |
| MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. | |
| CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| CL2022001612A1 (es) | Tieniloxazolonas y análogos | |
| MX2017000862A (es) | Formulacion de factor viii. | |
| DOP2020000104A (es) | Métodos de uso y composiciones que contienen dulaglutida | |
| AR108616A1 (es) | Formulación combinada de tres compuestos antivirales |